Ventures

Syntaxin developed bacterial-based protein therapeutics that inhibit cell secretion for the treatment of neurological, inflammatory and endocrine diseases.

Develops patches for desensitization of food allergy using epicutaneous delivery. The lead program is in late stage clinical trials for peanut allergy desensitization.

Developed VTS-270 to treat patients with Niemann-Pick Disease Type C.

Sanifit is a drug development company that is developing treatments for calcification disorders where hydroxyapatite (HAP) crystals form and grow in blood vessels, leading to stiffer and narrower arteries.

Thesan Pharmaceuticals developed novel therapeutics for disorders of the skin.

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Developed dermatological drugs, the lead being an H4 receptor antagonist tested in Atopic Dermatitis and Psoriasis patients.

Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases such as non-functioning pituitary adenoma (NFPA).

Enliven Therapeutics is developing a novel, chronic, oral treatment for patients with sickle cell disease and other haemoglobinopathies.

Acacia Pharma is a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.